Loading chat...
MS SB2085
Bill
AI Summary
-
Allows pharmacists to substitute FDA-approved interchangeable biosimilar products for prescribed biological products under specified conditions
-
Requires prescriber prohibition of substitution must be documented in writing, verbally, or electronically
-
Mandates pharmacist notification and patient consent prior to substitution, and notification of prescriber within five business days
-
Requires pharmacists and prescribers to maintain written records of biosimilar substitutions for at least ten years
-
Directs State Board of Pharmacy to maintain public website list of FDA-determined interchangeable biosimilar products; effective July 1, 2013
Legislative Description
Prescription biosimilar product; provide for substitution by pharmacists.
Last Action
Died In Committee
2/5/2013